Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC.

ABSTRACT: Background/Objectives: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid proliferation, early metastasis, and near-universal relapse after initial therapy. While chemo-immunotherapy modestly improves first-line outcomes, survival after progression remains poor and highlights the urgent need for biomarker-directed strategies. Methods: A comprehensive literature search was conducted using major medical databases looking at key relevant studies on SCLC antibody studies. All authors reviewed the literature, assessed study quality, and interpreted the results from each study. Results: Recent advances in antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) have transformed therapeutic development by targeting antigens selec

SUBMITTER: Wang K 

PROVIDER: S-EPMC12821401 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature